MRS2P1

Across TCGA pan-cancer cohorts, MRS2P1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MRS2P1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MRS2P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRS2P1 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

BLCA, KIRC, and UCEC are the cancer types where MRS2P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRS2P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	+0.070	.006	6	view →
KIRC	Male	II,III,IV	−0.013	.001	4	view →
UCEC	All	All	+0.047	.032	2	view →
PRAD	All	All	+0.030	.004	2	view →
LUSC	Male	II,III,IV	−0.015	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MRS2P1–BLCA

Open the BLCA breakdown →